ArticleWorld journal of clinical oncology2025
Untargeted metabolomics analysis of serum metabolic signatures as novel biomarkers for gastric carcinoma.
Article in World journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Timeliness of postoperative serum carcinoembryonic antigen monitoring for predicting recurrence after gastric cancer surgery.World journal of gastrointestinal surgery · 2026Article
- Metabolomics identifies candidate diagnostic biomarkers for pituitary apoplexy.Frontiers in endocrinology · 2026Article
- Advancing early detection of gastric cancer through serum cytokine profiling.World journal of clinical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn recent years, metabolomics has emerged as a novel platform for biomarker discovery. However, the metabolic profiles associated with gastric carcinoma (GC) remain insufficiently explored.
aimTo examine the differences in metabolites between patients with GC and healthy controls, with the objective of identifying potential serum biomarkers for GC diagnosis through a non-targeted metabolomics approach.
methodsAn untargeted metabolic analysis was conducted on serum samples from 6 patients with GC and 6 healthy controls. Subsequently, the differential metabolites identified were further validated in serum samples from an expanded cohort of 50 patients with GC and 50 healthy controls. The discriminative capacity of differential metabolites in distinguishing patients with GC from healthy controls was assessed utilizing the receiver operating characteristic curve analysis. The association between the serum levels of differential metabolites and the disease severity, as determined by the tumor-node-metastasis staging system, was evaluated using Spearman's rank correlation coefficient.
resultsOur findings revealed a significant alteration in the metabolic profile, characterized by 111 up-regulated and 55 down-regulated metabolites in patients with GC compared to healthy controls. Among the top 10 up-regulated metabolites, the serum concentrations of eight metabolites including fenpiclonil, methyclothiazide, 5-hydroxyindoleacetate, 3-pyridinecarboxylic acid, guanabenz, 2,2-dichloro-N-(3-chloro-1,4-dioxo-2-naphthyl) acetamide, epigallocatechin gallate, and dimethenamid, were further validated to be significantly elevated in a cohort of 50 patients diagnosed with GC compared to 50 healthy control subjects (
conclusionThis study provides insights into the metabolic alterations associated with GC, and the identification of these biomarkers may enhance the clinical detection and management of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.